Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector (Q74471964)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

Katsuyuki Kuratsukuri

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Ching Y Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Tomomichi Sone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Nobuyasu Nishisaka

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Richard F Jones

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Gabriel P Haas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

67-73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Early androgen deprivation for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Prostate Cancer — The Therapeutic Challenge of Locally Advanced Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Progress in human tumour immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Clinical trials of immunotherapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Antibody-targeted immunotherapy for treatment of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Progress in active specific immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900211-7

7 January 2021

10.1016/S0302-2838(02)00211-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121733%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference